Blueprint Medicines (BPMC) Tops Q1 EPS by 50c

Blueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($2.15), $0.50 better than the analyst estimate of ($2.65). Revenue for the quarter came in at $63.3 million versus the consensus estimate of $41.85 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c